High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial

Trial Results:
The Phase IIIb STEP UP trial showed that high-dose Wegovy (semaglutide 7.2 mg) achieved a 20.7% weight loss in obese adults after 72 weeks, compared to 17.5% with the standard dose (2.4 mg) and 2.4% with placebo12.

Safety Profile:
The high dose was reported to have a safe and well-tolerated profile, with mild to moderate gastrointestinal symptoms being the most common adverse effects24.

Significant Weight Loss:
33.2% of patients on the high dose achieved a weight loss of 25% or more, compared to 16.7% with the standard dose and 0.0% with placebo12.

Treatment Adherence:
When accounting for treatment adherence, the high dose led to a weight loss of 18.7%, surpassing the 15.6% achieved with the standard dose and the 3.9% with placebo12.

Future Studies:
The STEP UP T2D trial, evaluating the high dose in adults with type 2 diabetes and obesity, is ongoing, with results expected in the coming months24.

Sources:

1. https://www.clinicaltrialsarena.com/news/novo-nordisk-trial-semaglutide/

2. https://www.biospace.com/press-releases/novo-nordisk-a-s-semaglutide-7-2-mg-s-c-achieved-20-7-weight-loss-in-the-step-up-obesity-trial-and-18-7-regardless-of-treatment-adherence

4. https://www.outsourcing-pharma.com/Article/2025/01/21/trial-shows-high-dose-wegovy-can-increase-weight-loss-effects/